Comparing the current results to its competitors, Repligen reported Revenue increase in the 2 quarter 2026 by 11.93 % year on year. The sales growth was above Repligen's competitors' average revenue growth of 4.99 %, achieved in the same quarter.
Company's competitiveness improved within Overall company, with revenue growth of 11.93 % and its market share increased to approx. 2.74 %. << More on RGEN Market Share.
*Market share is calculated based on total revenue.
Bio-Techne Corp operates as a global life sciences company that provides innovative tools and solutions. They offer a diverse portfolio of products, including research reagents, diagnostic controls, and protein analysis tools, catering to the needs of academia, pharmaceutical and biotechnology companies. The company focuses on driving scientific advancements and aiding researchers in understanding biological systems by developing cutting-edge technologies and delivering high-quality products and services.
Qiagen N.V. is a Dutch multinational company that operates in the field of molecular diagnostics and sample preparation technologies. Their business model revolves around developing and manufacturing products and solutions for molecular testing, enabling researchers and healthcare professionals to analyze biological samples and gain insights into diseases and genetic variations. Qiagen N.V. primarily generates revenue through the sale of instruments, consumables, and related services to customers in various market segments including academia, pharmaceuticals, and diagnostics.
Danaher Corporation operates a diversified business model centered on developing advanced technologies and solutions across multiple sectors, particularly life sciences, diagnostics, dental, and environmental. The company emphasizes continuous innovation and operational excellence, leveraging its proprietary technologies to drive growth and improve efficiency. By strategically acquiring and integrating complementary businesses, Danaher enhances its product offerings while expanding its global market presence.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Sources:
Repligen Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Repligen Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
